BridgeBio Competitors
| BBIO Stock | USD 77.87 2.04 2.55% |
BridgeBio Pharma vs Jazz Pharmaceuticals Correlation
Poor diversification
The correlation between BridgeBio Pharma and JAZZ is 0.75 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding BridgeBio Pharma and JAZZ in the same portfolio, assuming nothing else is changed.
Moving together with BridgeBio Stock
Moving against BridgeBio Stock
| 0.92 | SPRB | Spruce Biosciences Common | PairCorr |
| 0.89 | WINT | Windtree Therapeutics | PairCorr |
| 0.89 | CUE | Cue Biopharma | PairCorr |
| 0.89 | MDCX | Medicus Pharma | PairCorr |
| 0.87 | DRMA | Dermata Therapeutics | PairCorr |
BridgeBio Pharma Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between BridgeBio Pharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of BridgeBio and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of BridgeBio Pharma does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between BridgeBio Stock performing well and BridgeBio Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BridgeBio Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RVMD | 2.15 | 1.23 | 0.81 | 3.82 | 0.49 | 5.23 | 32.00 | |||
| IONS | 1.62 | 0.09 | 0.04 | 0.20 | 1.71 | 3.19 | 8.64 | |||
| ASND | 1.96 | 0.27 | 0.07 | (0.38) | 2.09 | 4.74 | 11.01 | |||
| SMMT | 2.66 | (0.38) | 0.00 | (0.11) | 0.00 | 5.41 | 23.61 | |||
| ROIV | 1.61 | 0.35 | 0.18 | 0.98 | 1.44 | 4.37 | 9.44 | |||
| MRNA | 3.60 | 0.84 | 0.22 | 0.44 | 3.62 | 10.85 | 22.21 | |||
| BMRN | 1.71 | 0.07 | 0.03 | 0.19 | 1.68 | 3.20 | 22.06 | |||
| EXEL | 1.72 | 0.33 | 0.17 | 0.44 | 1.58 | 4.60 | 11.45 | |||
| RNA | 1.39 | 0.62 | 0.67 | 0.65 | 0.00 | 1.23 | 42.94 | |||
| JAZZ | 1.66 | 0.43 | 0.15 | (0.50) | 1.68 | 3.66 | 25.96 |
Cross Equities Net Income Analysis
Compare BridgeBio Pharma and related stocks such as Revolution Medicines, Ionis Pharmaceuticals, and Ascendis Pharma AS Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVMD | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (41.8 M) | (47.7 M) | (108.2 M) | (187.1 M) | (248.7 M) | (436.4 M) | (600.1 M) | (540.1 M) | (513.1 M) |
| IONS | (4.5 M) | (84.8 M) | (65.5 M) | (60.6 M) | (39 M) | (88.3 M) | (86.6 M) | 346 K | 273.7 M | 294 M | (487 M) | (28.6 M) | (269.7 M) | (366.3 M) | (453.9 M) | (408.5 M) | (388.1 M) |
| ASND | 1.2 M | 1.2 M | 1.2 M | 4.1 M | (9.7 M) | (32.9 M) | (68.5 M) | (123.9 M) | (130.1 M) | (218 M) | (419 M) | (383.6 M) | (583.2 M) | (481.4 M) | (378.1 M) | (340.3 M) | (357.3 M) |
| SMMT | (42 K) | (4.2 M) | (6.7 M) | (10.1 M) | (17.1 M) | (24.3 M) | (21.4 M) | (28.5 M) | 9.9 M | 5 M | (52.7 M) | (86.1 M) | (78.8 M) | (614.9 M) | (221.3 M) | (199.2 M) | (189.2 M) |
| ROIV | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | 1.2 B | (809.2 M) | (845.3 M) | (1 B) | 4.3 B | (172 M) | (197.8 M) | (187.9 M) |
| MRNA | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (1.1 M) | (216.2 M) | (255.9 M) | (384.7 M) | (514 M) | (747.1 M) | 12.2 B | 8.4 B | (4.7 B) | (3.6 B) | (4.1 B) | (3.9 B) |
| BMRN | (12.3 M) | (53.8 M) | (114.3 M) | (176.4 M) | (134 M) | (171.8 M) | (630.2 M) | (117 M) | (77.2 M) | (23.8 M) | 854 M | (64.1 M) | 141.6 M | 167.6 M | 426.9 M | 490.9 M | 515.4 M |
| EXEL | (15.7 M) | 75.7 M | (147.6 M) | (244.8 M) | (268.5 M) | (169.7 M) | (70.2 M) | 154.2 M | 690.1 M | 321 M | 111.8 M | 231.1 M | 182.3 M | 207.8 M | 521.3 M | 599.5 M | 629.4 M |
| RNA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (24.7 M) | (44 M) | (117.4 M) | (169.1 M) | (212.2 M) | (322.3 M) | (290.1 M) | (275.6 M) |
| JAZZ | (24.8 M) | 125 M | 288.6 M | 216.3 M | 58.4 M | 329.5 M | 396.8 M | 487.8 M | 447.1 M | 523.4 M | 238.6 M | (329 M) | (224.1 M) | 414.8 M | 560.1 M | 644.1 M | 676.3 M |
BridgeBio Pharma and related stocks such as Revolution Medicines, Ionis Pharmaceuticals, and Ascendis Pharma AS Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in BridgeBio Pharma financial statement analysis. It represents the amount of money remaining after all of BridgeBio Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.BridgeBio Pharma Competitive Analysis
The better you understand BridgeBio Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, BridgeBio Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across BridgeBio Pharma's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
BridgeBio Pharma Competition Performance Charts
Five steps to successful analysis of BridgeBio Pharma Competition
BridgeBio Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by BridgeBio Pharma in relation to its competition. BridgeBio Pharma's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of BridgeBio Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact BridgeBio Pharma's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to BridgeBio Pharma, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your BridgeBio Pharma position
In addition to having BridgeBio Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aluminum Thematic Idea Now
Aluminum
Companies involved in production of aluminum. The Aluminum theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aluminum Theme or any other thematic opportunities.
| View All Next | Launch |
Check out BridgeBio Pharma Correlation with its peers. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.21) | Revenue Per Share | Quarterly Revenue Growth 43.18 | Return On Assets | Return On Equity |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.